Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company focused on mRNA medicines, with multiple approved vaccines and a broad clinical pipeline. The MRNA news page on Stock Titan aggregates company announcements, investor updates and regulatory developments so readers can follow how Moderna’s strategy and pipeline progress translate into real-world events.
Investors and observers can use this feed to track commercial updates on products such as Spikevax, mRESVIA and mNEXSPIKE, along with developments in late-stage respiratory programs like the seasonal influenza vaccine mRNA-1010, the flu/COVID combination vaccine mRNA-1083 and the Norovirus vaccine candidate mRNA-1403. News items often cover regulatory submissions and opinions from agencies including the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada and others.
The page also surfaces pipeline and clinical trial news in oncology and rare diseases, including updates on mRNA-4157 (intismeran autogene), mRNA-4359, mRNA-3927 for propionic acidemia and mRNA-3705 for methylmalonic acidemia. Announcements related to partnerships, such as CEPI’s funding commitment for the H5 pandemic influenza vaccine candidate mRNA-1018, appear here as well.
In addition, the MRNA news feed includes financial results, guidance and capital structure updates, such as quarterly earnings releases, multi-year financial frameworks and information on facilities like the $1.5 billion credit agreement. Corporate items, including participation in healthcare conferences, Analyst Day presentations and shareholder meeting outcomes, are also reflected.
By reviewing this consolidated news stream, readers can see how Moderna’s respiratory vaccine franchise, oncology and rare disease programs, manufacturing expansion and financing decisions evolve over time, all based on the company’s own disclosures and related announcements.
Moderna (NASDAQ: MRNA) is set to invest up to $500 million in building a state-of-the-art mRNA manufacturing facility in Africa. This facility aims to produce up to 500 million vaccine doses annually. The investment reflects Moderna's commitment to expanding its global manufacturing capacity and enhancing its mRNA platform, which has been pivotal in COVID-19 vaccine production. The company plans to begin the site selection process soon. Moderna has delivered over 500 million doses of its COVID-19 vaccine globally to date.
Moderna (NASDAQ: MRNA) has launched the Moderna Fellowship Program aimed at fostering a new generation of leaders in mRNA therapeutics and vaccine research. The initiative will select approximately 50 global fellows in its first year, focusing on infectious diseases. Dr. Greg Poland, an expert in infectious diseases, will chair the program. This effort underscores Moderna's commitment to supporting independent research and advancing mRNA-based innovations to improve patient care and population health.
Moderna, Inc. (NASDAQ: MRNA) announced that the European Medicines Agency has authorized a third dose of its COVID-19 vaccine, Spikevax, for severely immunocompromised individuals aged 12 years and older, to be administered at least 28 days after the second dose. Recent studies indicate that a third dose may enhance immune response in this vulnerable population. Moderna reaffirms its commitment to combatting COVID-19 through its mRNA technology, which has yielded effective vaccines and therapeutics.
Moderna, Inc. (NASDAQ: MRNA) has announced plans to invest in a new 462,000 sq. ft. science center in Cambridge, Massachusetts, aiming for LEED Zero certification. This facility will support its mRNA therapeutics and vaccines, focusing on sustainability and collaboration. Construction has begun, with phased move-in expected in 2023. Alexandria Real Estate Equities (NYSE: ARE) is the development partner, while Jones Lang LaSalle (NYSE: JLL) facilitated the site selection. Moderna's pipeline includes 37 programs, 22 of which are in clinical studies.
Moderna (Nasdaq: MRNA) announced that President Stephen Hoge, M.D., will join a fireside chat at Chardan’s Virtual 5th Annual Genetic Medicines Conference on October 5 at 1:00 p.m. ET. Investors can access a live webcast of the event on Moderna's website under “Events and Presentations.” The discussion will be archived for 30 days post-event. Moderna has evolved significantly in its 10 years, focusing on mRNA therapeutics and vaccines, including COVID-19, and has built a diverse clinical portfolio alongside robust manufacturing capabilities.
Moderna (MRNA) announced a supply agreement with the government of Peru for 20 million doses of its COVID-19 vaccine, with delivery commencing in Q1 2022. The vaccine is not yet approved for use in Peru, and Moderna will seek regulatory approvals prior to distribution. Corinne Le Goff, Moderna's CCO, expressed appreciation for the agreement, emphasizing the company's commitment to address the pandemic globally. The press release includes forward-looking statements regarding regulatory processes and delivery timelines, noting associated risks and uncertainties.
Moderna, Inc. (NASDAQ: MRNA) announces that Health Canada has granted full approval for SPIKEVAX (elasomeran mRNA vaccine), previously known as COVID-19 Vaccine Moderna. This marks a significant milestone as it's the first complete approval for SPIKEVAX. The approval is based on Phase 3 COVE study results, showing 93% efficacy with sustained protection for six months post-second dose. SPIKEVAX is indicated for individuals aged 12 and older, expanding its earlier emergency use for adults and adolescents. The company expresses gratitude towards Health Canada and the Canadian Government for their collaboration.
Moderna (MRNA) announces that its COVID-19 vaccine, mRNA-1273, remains highly effective against the Delta variant. A study involving 352,878 vaccinated individuals indicated an effectiveness rate of 87% against COVID-19 diagnosis and 96% against hospitalization. An analysis of their Phase 3 COVE study revealed a 36% reduction in breakthrough infections for those vaccinated more recently compared to those vaccinated earlier. The company advocates for a booster dose to enhance immunity and will share findings in a conference call.
Moderna, Inc. (NASDAQ: MRNA) has made significant advancements in its mRNA vaccine pipeline, as announced during its fifth annual R&D Day. Key highlights include the development of a combination respiratory vaccine for COVID-19 and flu, and a pediatric vaccine for RSV and hMPV. Interim Phase 1 data showed boosted neutralizing antibody titers in older adults for the RSV candidate. Additionally, a personalized cancer vaccine trial is fully enrolled. Moderna currently has 37 programs in development, including 22 in clinical studies.
Moderna, Inc. (MRNA) has partnered with National Resilience, Inc. to manufacture mRNA for its COVID-19 vaccine. This multi-year agreement will utilize Resilience's facility in Mississauga, Ontario, ensuring global distribution of the vaccine. The collaboration aims to broaden access to Moderna's vaccines and enhance pandemic response capabilities. Additionally, Moderna has initiated a collaboration with Canada to establish a state-of-the-art mRNA manufacturing facility, further solidifying its commitment to expanding healthcare solutions against respiratory viruses.